PTHN Patheon N.V.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Patheon N.V. to Thermo Fisher Scientific Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Patheon N.V. (NYSE:PTHN) stock prior to May 15, 2017.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Patheon to Thermo Fisher Scientific Inc. (NYSE:TMO) for $35 per share. To learn more about the action and your rights, go to:

http://www.zlkdocs.com/PTHN-Info-Request-Form-ma-5885

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Eduard Korsinsky, Esq.

30 Broad Street - 24th Floor

New York, NY 10004

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

EN
21/06/2017

Underlying

PTHNPatheon N.V.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Patheon N.V.

 PRESS RELEASE
Free
PTHN PATHEON N.V.

Patheon Announces Intent to Voluntarily Delist from the NYSE Subject t...

DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (NYSE: PTHN) (“Patheon”), today announced that it has submitted written notice to the New York Stock Exchange (the “NYSE”) of its intention to voluntarily delist its ordinary shares, par value €0.01 per share (the “Shares”), from the NYSE. The voluntary delisting is subject to and conditioned upon (1) the initial expiration of the tender offer at 5:00 p.m., New York City time, on August 2...

August 22, 2017 1 EN
 PRESS RELEASE
Free
PTHN PATHEON N.V.

Patheon to Invest $45 Million, Expanding Capabilities to Support Conti...

DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, today announced that it expects to invest approximately $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities. “As outsourcing of Pharma development and manufacturing services continues to grow, our customers will need even more advanced technologies and customized solutions to meet their ...

June 29, 2017 1 EN
 PRESS RELEASE
Free
PTHN PATHEON N.V.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Co...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Patheon N.V. (NYSE:PTHN) stock prior to May 15, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Patheon to Thermo Fisher Scientific Inc. (NYSE:TMO) for $35 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/PTHN-Info-Request-Form-ma-5885 or contact J...

June 21, 2017 1 EN
 PRESS RELEASE
Free
PTHN PATHEON N.V.

Patheon Reports Fiscal 2017 Second Quarter

DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended April 30, 2017. Second quarter 2017 revenue was $483 million, compared to $469 million in the prior-year period, and second quarter 2017 adjusted EBITDA was $94 million, compared to $98 million in the prior-year period. Revenue for the first six months of fiscal 2017 was $941 million, compared to $875 million in the comparable fisc...

June 8, 2017 1 EN
 PRESS RELEASE
Free
PTHN PATHEON N.V.

Patheon Completes Sterile Expansion Project at Greenville, NC Manufact...

DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that it has completed an expansion project at its Greenville, NC manufacturing site. The company invested approximately $26 million to update one of its sterile Pharmaceutical Development Services (PDS) suites and to build a state-of-the-art, fully integrated sterile PDS suite which are compliant with regulatory authorities. The PDS Sui...

May 8, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch